
Helus Pharma depression drug succeeds in late study
Helus Pharma reported that its experimental psychedelic drug HLP003 significantly reduced depression symptoms in a late-stage trial. US-listed shares rose over 20 percent in premarket trading following the positive results.

Helus Pharma shares jumped 20% in premarket trading on Monday after its experimental psychedelic depression drug succeeded in a late-stage trial. The treatment, HLP003, showed statistically significant improvements compared with a placebo in patients with major depressive disorder. Jefferies analysts said the drug's efficacy exceeded investor expectations, noting that remission rates at week six could represent a differentiating attribute over rival therapies.






